NTF Therapeutics

NTF Therapeutics is a private U.S. biotechnology company focused on neurotrophic factor therapeutics, with work centered on engineered neurturin variants. Publicly visible evidence of the company's activity is primarily patent-related, including intellectual property covering neurturin molecules designed to reduce heparin and heparan sulfate binding while retaining neurotrophic activity. The scientific rationale appears to be improving delivery and therapeutic efficiency of neurturin-based proteins for neurodegenerative disorders such as Parkinson's disease. Available business-directory sources indicate a small Minnesota-based pharmaceutical preparation company led by Richard Penn, but there is limited evidence of an active disclosed clinical pipeline, partnerships, or commercialization activities. Overall, NTF Therapeutics appears to be an early-stage, patent-driven neurodegeneration-focused biotech rather than a clinically advanced operating pharma company.